

Contents

Author biographies	vii
Abbreviations	ix
Dedication	xiii
1 Introduction	1
Historical perspective	1
Epidemiology	3
Etiology	4
Clinical manifestations	4
Pathophysiology	5
References	7
2 Diagnosis	9
Diagnostic laboratory tests	9
Differential diagnosis	15
Clinical risk scores	16
References	17
3 Monitoring response to treatment	21
Hematological response	21
Cytogenetic response	21
Molecular monitoring methods	23
Rising <i>BCR-ABL</i> levels	26
Pharmacokinetics	28
Monitoring protocol in different clinical settings	28
References	30
4 Management of patients with chronic myeloid leukemia	35
Current approach to treatment	35
Which tyrosine kinase inhibitor to use?	36
Determining the treatment goals	42
Achieving treatment goals	45

Identifying high-risk patients based on early molecular response	46
Risk-adapted therapy	47
Other promising frontline approaches	48
References	49
5 Challenges of treatment: tyrosine kinase inhibitor-resistant chronic myeloid leukemia	53
Mechanisms of resistance	53
Therapeutic options for patients who fail frontline therapy	59
Other tyrosine kinase inhibitors after failure of frontline therapy	60
Allogeneic stem cell transplantation	61
References	62

Handbook of Chronic Myeloid Leukemia

Hughes, T.P.; Ross, D.M.; Melo, J.V.

2014, XIII, 65 p. 14 illus., 12 illus. in color., Softcover

ISBN: 978-3-319-08349-0